BIOTECHNOLOGY VALUE FUND L P 13D/13G Filings for TScan Therapeutics, Inc. (TCRX)

BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for TScan Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2024-11-14
4:40 pm
Purchase		 2024-09-30 13G TScan Therapeutics, Inc.
TCRX		 BIOTECHNOLOGY VALUE FUND L P 5,073,003
9.990%		 658,093increase
(+14.91%)		 Filing
2023-06-05
4:45 pm
Purchase		 2023-05-26 13G TScan Therapeutics, Inc.
TCRX		 BIOTECHNOLOGY VALUE FUND L P 4,414,910
9.990%		 4,414,910increase
(New Position)		 Filing